Protego, a prominent B2B news brand specializing in the biotech and medtech industries, has announced it has secured $130,000,000 in a recent funding round from investors. The company is widely recognized for its comprehensive and in-depth coverage of the drug and device development universe, as well as the significant financial activities within the sector, including financing rounds, deals, IPOs, and mergers and acquisitions. Protego's journalistic approach focuses on delivering unvarnished insights into the companies and individuals shaping the biotech and medtech landscape, leveraging a network of contacts to provide exclusive reporting.
The company's offerings extend beyond daily news coverage, encompassing longer-form content, podcasts such as 'The Top Line,' and industry events. Protego publishes a family of specialized publications, including Fierce Biotech, Fierce Medtech, Fierce Biotech Research, Fierce CRO, Fierce Life Sciences Weekly Digest, and Fierce Cell & Gene Therapy, all designed to deliver revealing insights straight to its professional audience. This substantial investment of $130,000,000 underscores significant investor confidence in Protego's established market position and its continued potential within the specialized life sciences media sphere.
Protego plans to use the newly raised capital to support strategic growth initiatives across its operations. This capital infusion is expected to enable the company to expand its editorial capabilities, enhance its technological infrastructure for content delivery, and further develop its diverse platforms, including its podcasts and events. The funding will also support efforts to strengthen its market leadership and continue providing critical, timely information to professionals across the global biotech and medtech ecosystems.
This investment positions Protego to further solidify its role as a leading source of essential industry intelligence, aiming to expand its reach and continue its trajectory of growth in serving the specialized information needs of the life sciences community.
